Genmab A/S Stock Earnings Estimates Boosted by HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Stock analysts at HC Wainwright upped their Q3 2026 EPS estimates for Genmab A/S in a research report issued to clients and investors on Monday, October 19th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.49 per share for the quarter, up from their previous forecast of $0.48. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.20 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.46 EPS, FY2026 earnings at $1.51 EPS, Q1 2027 earnings at $0.35 EPS, Q2 2027 earnings at $0.59 EPS, Q3 2027 earnings at $0.60 EPS and FY2027 earnings at $2.15 EPS.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.12 billion.

A number of other research firms also recently commented on GMAB. Guggenheim raised their target price on Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a report on Monday, October 5th. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and upped their price target for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. Truist Financial increased their price target on shares of Genmab A/S from $40.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Finally, New Street Research set a $43.00 price objective on shares of Genmab A/S in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.39.

Genmab A/S Trading Up 1.5%

NASDAQ:GMAB opened at $39.07 on Wednesday. The stock has a fifty day moving average price of $34.68 and a two-hundred day moving average price of $29.94. The stock has a market capitalization of $24.38 billion, a price-to-earnings ratio of 27.70, a PEG ratio of 1.80 and a beta of 0.81. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $40.17.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC lifted its holdings in shares of Genmab A/S by 26.4% in the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after purchasing an additional 921,700 shares in the last quarter. First Trust Advisors LP grew its position in shares of Genmab A/S by 84.3% in the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after purchasing an additional 1,126,069 shares during the last quarter. Quantinno Capital Management LP increased its stake in shares of Genmab A/S by 14.4% during the 1st quarter. Quantinno Capital Management LP now owns 282,498 shares of the company’s stock worth $7,579,000 after purchasing an additional 35,588 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Genmab A/S by 1.8% during the 1st quarter. Royal Bank of Canada now owns 150,135 shares of the company’s stock worth $4,029,000 after purchasing an additional 2,637 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC raised its position in shares of Genmab A/S by 164.1% during the 2nd quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock worth $2,806,000 after purchasing an additional 63,484 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.